Search research articles
Contact Us
Filters
Showing results (1001-1010 of 1,066) with videos related to
Page
of 107
Sort By:
Nature Genetics
|
February 2, 2000
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns
J F Costello, M C Frühwald, D J Smiraglia, et al.
JCI Insight
|
January 19, 2021
CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma
Hadas Lewinsky, Emine G Gunes, Keren David, et al.
Blood
|
March 13, 2012
Regulation of acute graft-versus-host disease by microRNA-155
Parvathi Ranganathan, Catherine E A Heaphy, Stefan Costinean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2011
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study
Klaus H Metzeler, Kati Maharry, Michael D Radmacher, et al.
Nature Communications
|
April 6, 2023
Factor Xa cleaves SARS-CoV-2 spike protein to block viral entry and infection
Wenjuan Dong, Jing Wang, Lei Tian, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 17, 2014
Expression and prognostic impact of lncRNAs in acute myeloid leukemia
Ramiro Garzon, Stefano Volinia, Dimitrios Papaioannou, et al.
Blood
|
July 27, 2010
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Susan P Whitman, Kati Maharry, Michael D Radmacher, et al.
Nature
|
July 19, 2019
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Anna M Paczulla, Kathrin Rothfelder, Simon Raffel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 31, 2019
A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma
Elizabeth L McMichael, Brooke Benner, Lakhvir S Atwal, et al.
Journal for Immunotherapy of Cancer
|
May 22, 2023
Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia
Anil Kumar, Adeleh Taghi Khani, Caroline Duault, et al.
Page
of 107
Search research articles
Search
Showing results (1001-1010 of 1,066) with videos related to
Sort By:
Page
of 107
Nature Genetics
|
February 2, 2000
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns
J F Costello, M C Frühwald, D J Smiraglia, et al.
JCI Insight
|
January 19, 2021
CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma
Hadas Lewinsky, Emine G Gunes, Keren David, et al.
Blood
|
March 13, 2012
Regulation of acute graft-versus-host disease by microRNA-155
Parvathi Ranganathan, Catherine E A Heaphy, Stefan Costinean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2011
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study
Klaus H Metzeler, Kati Maharry, Michael D Radmacher, et al.
Nature Communications
|
April 6, 2023
Factor Xa cleaves SARS-CoV-2 spike protein to block viral entry and infection
Wenjuan Dong, Jing Wang, Lei Tian, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 17, 2014
Expression and prognostic impact of lncRNAs in acute myeloid leukemia
Ramiro Garzon, Stefano Volinia, Dimitrios Papaioannou, et al.
Blood
|
July 27, 2010
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Susan P Whitman, Kati Maharry, Michael D Radmacher, et al.
Nature
|
July 19, 2019
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Anna M Paczulla, Kathrin Rothfelder, Simon Raffel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 31, 2019
A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma
Elizabeth L McMichael, Brooke Benner, Lakhvir S Atwal, et al.
Journal for Immunotherapy of Cancer
|
May 22, 2023
Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia
Anil Kumar, Adeleh Taghi Khani, Caroline Duault, et al.
Page
of 107